Hongbo Yang

Baojiao Xiong, Boheng Chen, Chengzhi Wang et al. · baidu, tencent-ai

We present BlueLM-2.5-3B, a compact and unified dense Multimodal Large Language Model (MLLM) designed for efficient edge-device deployment, offering strong general-purpose and reasoning capabilities. To the best of our knowledge, this is the first 3B-scale MLLM to support both thinking and non-thinking modes, while also enabling explicit control over thinking token budget. BlueLM-2.5-3B is developed through diversified data curation, key data resampling, hybrid heterogeneous reinforcement learning, and a high-performance training infrastructure. Our model achieves superior multimodal capacity while preserving competitive pure-text performance with only 2.9 billion parameters. We conduct comprehensive evaluations across a broad range of multimodal and text-only benchmarks. In thinking mode, BlueLM-2.5-3B achieves comparable performance to Qwen3-4B on text-only benchmarks, and trails the larger Kimi-VL-A3B-16B by only about 5% on average across multimodal evaluations. In non-thinking mode, it outperforms Qwen2.5-VL-3B on the majority of multimodal benchmarks. Additionally, BlueLM-2.5-3B exhibits exceptional data efficiency. All of the aforementioned performance is achieved with substantially less total training data than Qwen2.5-VL-3B and Qwen3-4B. We hope our work contributes to the advancement of high-performance, on-device MLLMs and provides meaningful insights to the research community.

Nan Mu, Hongbo Yang, Chen Zhao

Background and Objective: High-throughput multi-omics technologies have proven invaluable for elucidating disease mechanisms and enabling early diagnosis. However, the high cost of multi-omics profiling imposes a significant economic burden, with over reliance on full omics data potentially leading to unnecessary resource consumption. To address these issues, we propose an uncertainty-aware, multi-view dynamic decision framework for omics data classification that aims to achieve high diagnostic accuracy while minimizing testing costs. Methodology: At the single-omics level, we refine the activation functions of neural networks to generate Dirichlet distribution parameters, utilizing subjective logic to quantify both the belief masses and uncertainty mass of classification results. Belief mass reflects the support of a specific omics modality for a disease class, while the uncertainty parameter captures limitations in data quality and model discriminability, providing a more trustworthy basis for decision-making. At the multi omics level, we employ a fusion strategy based on Dempster-Shafer theory to integrate heterogeneous modalities, leveraging their complementarity to boost diagnostic accuracy and robustness. A dynamic decision mechanism is then applied that omics data are incrementally introduced for each patient until either all data sources are utilized or the model confidence exceeds a predefined threshold, potentially before all data sources are utilized. Results and Conclusion: We evaluate our approach on four benchmark multi-omics datasets, ROSMAP, LGG, BRCA, and KIPAN. In three datasets, over 50% of cases achieved accurate classification using a single omics modality, effectively reducing redundant testing. Meanwhile, our method maintains diagnostic performance comparable to full-omics models and preserves essential biological insights.